The short answer
Chromium may affect glucose control. Review the product before combining it with repaglinide; the exact added low-blood-sugar risk has not been measured.
What this answer covers
Supplemental chromium, with elemental amount and chemical form recorded.
- Supplement or preparation
- Chromium
- Medication ingredient
- repaglinide
What the human evidence shows
Chromium picolinate improved glucose-related measures in a study with glipizide, a different insulin-releasing drug. The broader chromium evidence is inconsistent and does not measure this exact pair’s hypoglycemia rate.
Why your treatment context matters
Repaglinide stimulates insulin release and can cause low blood sugar. The prescriber should consider the full regimen, meals and prior low readings before deciding whether additional monitoring is useful.
Check the supplement preparation
The Supplement Facts amount is elemental chromium. A high-dose picolinate study cannot define the effect of a routine multivitamin or every chromium form.
Keep the prescribed medicine plan
Take repaglinide within thirty minutes before meals as prescribed and skip its dose when a meal is skipped. Review supplement changes with the prescriber instead of inventing a separation interval or adjusting the medicine yourself.
Watch for low blood sugar
Follow your existing glucose-monitoring and low-blood-sugar treatment plan. New sweating, shakiness, hunger or confusion warrants a glucose check when possible. Severe confusion, a seizure or inability to swallow safely needs emergency help.
Evidence and practical considerations
Side effects & toxicity
Conditional glucose-monitoring concern follows from supplement glucose effects and the exact medicine context. This is not direct evidence of increased hypoglycemia or altered drug absorption.
- Exact scope
- Supplemental chromium, with elemental amount and chemical form recorded. with Exact repaglinide oral tablets. Exact RxNorm IN73044 oral repaglinide; CYP2C8, CYP3A4 and transporters must not be equated with nateglinide pathways.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- No exact pair human interaction trial identified. Preparation-specific positive and null results do not establish a universal effect, safe dose, spacing rule or drug concentration change.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed repaglinide.
Insulin secretagogue with hypoglycemia risk; within thirty minutes before meals and skip dose with skipped meal; nicotinic acid may reduce glucose-lowering effect, salicylates may increase it.
How this applies: Exact RxNorm IN73044 oral repaglinide; CYP2C8, CYP3A4 and transporters must not be equated with nateglinide pathways.
No universal supplement dose, interval, event rate or untested formulation equivalence.
Source 2: official nutrient guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: People considering chromium supplements.
Glucose-control findings are inconsistent; chromium may add to effects of antidiabetes medicines and increase hypoglycemia risk.
How this applies: Nutrient-only risk context.
General precaution, no exact nateglinide or repaglinide event rate; nutrient intake differs from high-dose picolinate trials.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes receiving glipizide GITS.
Insulin sensitivity and glycemic control improved.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Different insulin secretagogue and high-dose picolinate; no nateglinide or repaglinide levels or exact-pair hypoglycemia estimate.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. |
Article revision: afc306093f615b75
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.